Chimeric proteins for diagnosis and treatment of diabetes
AssigneeAlexion Pharmaceuticals, Inc.
InventorsYi Wang, John Mueller, Louis A. Matis
Life of this patent
Estimating the term…
Loading patent…
AssigneeAlexion Pharmaceuticals, Inc.
InventorsYi Wang, John Mueller, Louis A. Matis
Estimating the term…
Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins of the invention are useful in predicting risk of onset of Type 1 diabetes, determining prognosis of Type 1 diabetes patients early in disease progression, and in evaluating patients for suitability as recipients of transplants of pancreatic cells or tissues. The administration of the proteins of the invention in accordance with the immunomodulatory methods of the invention results in beneficial effects on disease development and severity in patients suffering from or predicted to be at risk of developing Type 1 diabetes, as well as on the outcome of transplants of pancreatic cells or tissues in Type 1 diabetes patients.
A chimeric fusion protein comprising an amino terminus and a carboxyl terminus, wherein the protein comprises, in order, starting at the amino terminus, insulin chain B, insulin chain C and human GAD 65 peptides 115-127, 247-286, and 473-519, wherein the insulin chain B and the at least one human GAD 65 peptide(s) are covalently linked and the chimeric fusion protein is capable of eliciting a human T cell response to insulin chain B and to each of the GAD 65 peptides.
A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 154 of SEQ ID NO:1.
A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 174 of SEQ ID NO:2.
A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 138 of SEQ ID NO:3.
A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 175 of SEQ ID NO:4.
A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 226 of SEQ ID NO:5.
A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 387 of SEQ ID NO:6.
A chimeric fusion protein comprising the amino acid sequence spanning amino acid residues 2 to 438 of SEQ ID NO:7.
Dependencies are inferred from the claim text.